{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Coral Laboratories Ltd
Coral Laboratories Ltd Stock Hits 52-Week Low at Rs.415
Shares of Coral Laboratories Ltd have declined to a fresh 52-week low of Rs.415 on 21 Jan 2026, marking a significant downturn amid persistent underperformance relative to the broader market and sector indices.
Coral Laboratories Ltd Stock Falls to 52-Week Low of Rs.419
Coral Laboratories Ltd has reached a new 52-week low of Rs.419, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial performance and valuation metrics.
Coral Laboratories Ltd is Rated Sell
Coral Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 12 January 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Coral Laboratories Ltd’s 1.00% Weekly Gain Masks Underlying Weaknesses
Coral Laboratories Ltd recorded a modest weekly gain of 1.00% from Rs.451.85 to Rs.456.35 between 29 December 2025 and 2 January 2026, slightly underperforming the Sensex which rose 1.35% over the same period. The week was marked by a new 52-week low on 31 December and a subsequent downgrade to a Strong Sell rating, reflecting ongoing financial and technical challenges despite a late-week recovery in share price.
Coral Laboratories Ltd Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals
Coral Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 31 Dec 2025. This revision reflects deteriorating financial performance, unfavourable valuation metrics, and a shift towards bearish technical indicators, signalling heightened risk for investors.
Coral Laboratories Ltd Stock Falls to 52-Week Low of Rs.429
Coral Laboratories Ltd touched a fresh 52-week low of Rs.429 today, marking a significant decline amid ongoing challenges in its financial performance and market positioning. Despite a modest intraday recovery, the stock remains below all key moving averages, reflecting persistent downward pressure.
Why is Coral Laboratories Ltd falling/rising?
On 26-Dec, Coral Laboratories Ltd experienced a significant decline in its share price, falling by 6.16% to close at ₹451.85. This drop follows a period of volatility and underperformance relative to both its sector and the broader market benchmarks.
Coral Laboratories: Analytical Revision Highlights Mixed Financial and Technical Signals
Coral Laboratories has undergone a revision in its evaluation metrics reflecting a nuanced market assessment shaped by recent financial results, valuation considerations, and technical indicators. This article analyses the key factors influencing the updated perspective on the pharmaceutical company’s stock performance and outlook.
Coral Laboratories Faces Challenging Market Conditions Amidst Mixed Financial and Technical Signals
Coral Laboratories, a player in the Pharmaceuticals & Biotechnology sector, is currently navigating a complex market environment marked by subdued financial performance and shifting technical indicators. Recent assessments reflect a cautious stance on the stock, driven by a combination of weak profitability metrics, subdued sales growth, and bearish technical trends, all set against a backdrop of broader market comparisons.
Coral Laboratories Stock Falls to 52-Week Low of Rs.431.1 Amidst Prolonged Downtrend
Shares of Coral Laboratories touched a fresh 52-week low of Rs.431.1 today, marking a continuation of the stock’s downward trajectory over the past week. The pharmaceutical and biotechnology company’s shares have declined over 9.6% in the last six trading sessions, reflecting ongoing pressures on its financial performance and market sentiment.
Coral Labs. Sees Revision in Market Evaluation Amidst Challenging Financial Trends
Coral Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting recent shifts in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, set against a backdrop of subdued market performance and sector dynamics.
Coral Laboratories Q2 FY26: Sharp Revenue Decline Raises Concerns Despite Margin Recovery
Coral Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹178.00 crores, reported concerning quarterly results for Q2 FY26, with net profit standing at ₹5.82 crores, representing a sequential increase of 127.34% from Q1 FY26's ₹2.56 crores, but a year-on-year decline of 8.78% from ₹6.38 crores in Q2 FY25. The stock has underperformed significantly over the past year, declining 34.70% whilst the Sensex gained 9.48%, resulting in a negative alpha of 44.18 percentage points.
Is Coral Labs. overvalued or undervalued?
As of November 17, 2025, Coral Labs is considered undervalued with a PE ratio of 10.25 and an EV to EBIT of 5.62, significantly lower than its expensive industry peers, suggesting potential for recovery despite a challenging year with a -40.17% stock return.
How has been the historical performance of Coral Labs.?
Coral Labs has shown significant growth in net sales and profitability from March 2023 to March 2025, with net sales rising from 78.12 Cr to 115.01 Cr and profit after tax increasing from 6.45 Cr to 24.16 Cr. However, cash flow from operating activities declined from 12.00 Cr to -1.00 Cr during the same period.
Is Coral Labs. overvalued or undervalued?
As of November 13, 2025, Coral Labs is considered a very attractive investment with strong valuation metrics, including a PE ratio of 9.66 and a Price to Book Value of 0.89, despite a year-to-date stock performance of -34.52%, indicating it is undervalued compared to peers like Sun Pharma and Divi's Lab.
Is Coral Labs. overvalued or undervalued?
As of November 12, 2025, Coral Labs is considered undervalued with a PE ratio of 10.04 and strong ROCE of 24.89%, despite a year-to-date stock performance of -31.95%, making it an attractive investment compared to its more expensive peers like Sun Pharma and Divi's Lab.
Is Coral Labs. overvalued or undervalued?
As of November 3, 2025, Coral Labs. is considered very attractive due to its undervalued status, highlighted by a PE Ratio of 9.59 and strong growth potential indicated by a PEG Ratio of 0.00, despite recent stock performance lagging behind the Sensex.
Is Coral Labs. overvalued or undervalued?
As of October 30, 2025, Coral Labs is considered undervalued with an attractive valuation grade, featuring a PE Ratio of 9.83, an EV to EBITDA of 4.40, and a Price to Book Value of 0.90, all significantly lower than its peers, indicating it remains a compelling investment opportunity despite recent underperformance against the Sensex.
Is Coral Labs. overvalued or undervalued?
As of October 28, 2025, Coral Labs. is considered very attractive due to its undervalued status, with strong financial ratios like a PE of 9.46 and an EV/EBITDA of 4.01, significantly lower than peers like Sun Pharma and Divi's Lab, despite a year-to-date stock performance lagging behind the Sensex.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
